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Hormone replacement therapy and risk of hip fracture:
population based case-control study
Karl Michaëlsson, John A Baron, Bahman Y Farahmand, Olof Johnell, Cecilia Magnusson,
Per-Gunnar Persson, Ingemar Persson, Sverker Ljunghall on behalf of the Swedish Hip Fracture
Study Group
Abstract
Objective: To determine the relative risk of hip
fracture associated with postmenopausal hormone
replacement therapy including the effect of duration
and recency of treatment, the addition of progestins,
route of administration, and dose.
Design: Population based case-control study.
Setting: Six counties in Sweden.
Subjects: 1327 women aged 50-81 years with hip
fracture and 3262 randomly selected controls.
Main outcome measure: Use of hormone
replacement therapy.
Results: Compared with women who had never used
hormone replacement therapy, current users had an
odds ratio of 0.35 (95 % confidence interval 0.24 to
0.53) for hip fracture and former users had an odds
ratio of 0.76 (0.57 to 1.01). For every year of therapy,
the overall risk decreased by 6% (3% to 9%): 4% (1%
to 8%) for regimens without progestin and 11% (6%
to 16%) for those with progestin. Last use between
one and five years previously, with a duration of use
more than five years, was associated with an odds ratio
of 0.27 (0.08 to 0.94). After five years without
hormone replacement therapy the protective effect
was substantially diminished ( − 7% to 48%). With
current use, an initiation of therapy nine or more
years after the menopause gave equally strong
reduction in risk for hip fracture as an earlier start.
Oestrogen treatment with skin patches gave similar
risk estimates as oral regimens.
Conclusions: Recent use of hormone replacement
therapy is required for optimum fracture protection,
but therapy can be started several years after the
menopause. The protective effect increases with
duration of use, and an oestrogen-sparing effect is
achieved when progestins are included in the regimen.
Introduction
Menopause is accompanied by accelerated bone loss1 2
and by an increase in the incidence of fractures such as
those of the hip.3 4 Many studies have shown that
hormone replacement therapy can reduce bone loss5 6
and the risk of hip fracture.7 However, the dose and
duration of treatment needed, the duration of the pro-
tective effect after treatment is stopped, the influence of
age at which treatment is initiated, and the efficacy of
different hormone replacement therapy regimens
remain unclear. We carried out a large, population
based, case-control study to evaluate these issues.
Subjects and methods
The study was conducted in the Swedish counties of
Stockholm, Uppsala, Västmanland, Örebro, Göteborg,
and Malmöhus. This largely urban area in the middle,
west, and south of Sweden includes nearly half of the
8.6 million inhabitants of Sweden.
Cases
We aimed to ascertain all cervical, pertrochanteric, or
subtrochanteric fractures of the proximal femur
among women resident in the study area who were
born in 1914 or after and treated during October 1993
to February 1995. Using hospital discharge records or
operation registers in all 24 hospitals in the study area
we identified 2597 possible incident cases. We excluded
those with a fracture due to malignancy (n = 26), high
energy trauma (n = 4), incorrect diagnosis (n = 41), old
fracture (n = 10), blindness (n = 5), birth outside of
Sweden (n = 202), a diagnosis of severe alcohol misuse,
psychosis, or senile dementia (n = 576) or death within
three months of the fracture (n = 123). All hospital
records were scrutinised to confirm eligibility and to
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There remained 1610 eligible cases. We sent these
women a comprehensive questionnaire at a mean
interval of 95 days (SD 23 days) after the fracture. At
the end of the study the Swedish inpatient register
identified 34 additional cases, who were also asked to
complete the questionnaire.
Controls
The controls were women born in Sweden randomly
selected from the national, continuously updated
population register. The selection was made the month
before the start of the study. Questionnaires were sent
to controls on six occasions evenly distributed through
the study period. Potential controls aged 70-80 years
were frequency matched (two controls: one case) to the
expected age distribution of hip fracture within county
of residence. Controls aged 50-69 years were also resi-
dents of the study area randomly selected from the
population register. These subjects were also possible
controls for a breast cancer study being conducted at
the same time with the same questionnaire to
coordinate research efforts. The frequency matching to
the expected number of breast cancer cases provided
numbers sufficient for two to four times as many
controls as hip fracture cases in each five year age
group and county of residence. Of all the 4872 candi-
date controls in the hip fracture analysis, 4059 were eli-
gible, 610 were born outside of Sweden, 157 died
before being approached, 44 had senility or psychosis,
and two were blind.
Data collection
We collected data through a postal questionnaire
focusing on reproductive history and use of exogenous
sex hormones, including oral contraceptives and
hormone replacement therapy. Information requested
included the doses and types of preparations, reason
for treatment, and the duration and dates of exposure.
Identification of treatments was aided by a picture
chart of all preparations commonly used in Sweden
during 1950-95. We also requested information on
current weight and height, education, dietary habits,
alcohol consumption, cigarette smoking, and physical
activity (childhood, aged 18 to 30, and recent years).
About half of the participants were approached by tele-
phone to obtain missing information.
Of those eligible, 1328 cases (82.5%) and 3312
controls (81.6%) answered the questionnaire; of these,
202 (15.2%) of the cases and 497 (15.0%) of the
controls responded solely by telephone in a less exten-
sive interview. Participants claiming natural menses
were classified as premenopausal (50 controls and one
case) and were excluded from the analysis.
Data analysis
Hormone replacement therapy preparations were cat-
egorised as low potency oestrogens, mainly oestriol,
progestins alone, unknown oestrogen preparations
with or without progestins, “medium potency”
oestrogens such as oestradiol and conjugated oestro-
gens given without progestins, and medium potency
oestrogens combined with progestins. Only the two
last groups were included in this analysis. The
oestrogen only and oestrogen plus progestin regimens
were further subdivided according to oestrogen dose.
Low dose was 1 mg of oestradiol, 0.325 mg conjugated
oestrogens, 5 ìg ethinyl oestradiol, or 25 ìg transder-
mal oestradiol per day; higher amounts were classed as
high dose. Current use was defined as ongoing
treatment at the time of fracture in cases and 95 days
before the first questionnaire was sent in controls (the
index dates). Former use was defined as discontinua-
tion before the index date. Total duration of hormone
replacement therapy, which excluded gaps in treat-
ment, was considered in continuous form since we
found a linear association with risk of hip fracture.
Time since last use and since menopause were
examined in three classes (12 months, 13-60 months,
and > 60 months for last use and 2 years, 3-8 years, or
>9 years for menopause).
Smoking status was defined as never, former, or
current smoking at the index date. Reports of
estimated leisure physical activity on a four point scale
in each of the three periods were summed and
condensed into a dichotomous variable as above or
below the median for the controls. Body mass index
was calculated as weight (kg) one year before complet-
ing the questionnaire divided by the square of height
(m2) and categorised into quartiles. Age was considered
in six classes: 50-54, 55-59, 60-64, 65-69, 70-74, and
75-81 years. Age at menopause was defined as the age
at the last menstrual period or age at bilateral
oophorectomy if it was one year or more before data
collection. If it was more recent women were
considered premenopausal. Women who had had a
hysterectomy, who had menses due to hormone
replacement therapy, or who had missing information
were considered postmenopausal if they had reached
the age when natural menopause had occurred in 90%
of women (53 years in current smokers and 55 years in
non-smokers) and otherwise as unknown. These
subjects were assigned an age at menopause (by smok-
ing status) corresponding to the mean age at natural
menopause in our data. Menopausal age was then used
as a three level variable (-45 years, 46-54 and >55).
Vasomotor symptoms at menopause were recorded as
present or absent. Education was classified as primary
school only versus a higher educational level.
We used odds ratios and 95% confidence intervals
computed by unconditional logistic regression as
Table 1 Characteristics of the participants and number of subjects providing







Age (years) 1327 72.5 (6.8) 3262 70.5 (7.7)
Age at menopause (years) 1327 50.0 (4.4) 3262 49.8 (4.2)
Age at menarche (years) 948 13.8 (1.5) 2618 13.6 (1.5)
Weight (kg) 1308 61.0 (11.1) 3233 66.8 (11.8)
Height (m) 1307 1.64 (0.07) 3235 1.63 (0.06)
Body mass index (kg/m2) 1294 22.2 (3.8) 3216 24.6 (4.2)
No (%) ever used postmenopausal oestrogen* 371 (28) 1189 (36.5)
Mean duration of use of hormone replacement therapy among ever users (months):
Any† 120 (9.0) 60.5 (73.3) 456 (14.0) 67.5 (79.9)
Without progestins 81 (6.1) 60.8 (65.8) 229 (7.0) 64.9 (84.0)
With progestins 56 (4.2) 43.6 (52.7) 274 (8.4) 59.0 (66.1)
With progesterone-like progestins 14 (1.1) 38.5 (33.9) 94 (2.9) 78.0 (73.1)
With testosterone-like progestins 45 (3.4) 50.0 (58.0) 222 (6.8) 56.0 (59.7)
With cyclic progestins 38 (2.3) 46.9 (47.7) 167 (5.1) 70.0 (70.1)
With continuous progestins 23 (1.7) 45.7 (60.3) 138 (4.2) 64.3 (61.2)
*Including oral or local treatment with oestriol or unspecified oestrogens.
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measures of association. Adjustment for cigarette
smoking, body mass index, leisure physical activity,
education, age at menopause, climacteric symptoms,
previous hip fracture, and county of residence
influenced the odds ratios only marginally—that is, less
than 10%. Consequently, the analyses presented here
were adjusted only for age and the indication of
hormone replacement therapy to prevent osteoporo-
sis, covariates which affected our odds ratios modestly.
Results
Table 1 summarises the characteristics of study partici-
pants. The hip fracture was cervical type in 817 (61.6%)
cases and trochanteric in 510 (38.4%) cases. About
93% of the cases had their first hip fracture during the
study period. Of those with an earlier fracture, 80% had
had a cervical fracture.
Ever use of any hormone replacement therapy with
medium potency oestrogens was associated with a sub-
stantial reduction in risk of fracture risk (table 2): odds
ratio 0.58 (95% confidence interval 0.46 to 0.75). There
was a 6% (3% to 9%) decrease in hip fracture risk for
every year of use of hormone replacement therapy of
any type. The odds ratio for current users was 0.36
(0.24 to 0.53). Among current users of any type of hor-
mone replacement therapy, the risk decreased by 9%
(5% to 13%) per year. Combined oestrogen-progestin
regimens conferred lower odds ratios than oestrogens
alone. Among current users, each year of oestrogen
use without progestin was associated with a 6% reduc-
tion in risk (1% to 12%) compared with 16% (8% to
24%) for combined treatment. The difference between
oestrogen and oestrogen plus progestin treatment was
less apparent among former users: the odds ratios per
year of use were 0.98 (0.92 to 1.04) and 0.93 (0.85 to
1.02) respectively.
Compared with never users of hormone replace-
ment therapy the odds of hip fracture was 0.27 (0.14 to
0.53) for current users of combined hormone replace-
ment therapy with fewer than 15 days/month of
progestins (usually 10-12 days/month) and 0.25 (0.13 to
0.48) for users of regimens with more than 15
days/month (mostly continuously combined exposure).
The odds ratios among former users were 0.99 (0.59 to
1.67) and 0.42 (0.18 to 0.98) respectively. The odds ratio
was 0.29 (0.15 to 0.56) for ever use of regimens with
progestins structurally related to progesterone and 0.48
(0.32 to 0.71) for ever use of progestins structurally
related to testosterone. Sixty four women had taken both
oestrogen alone and oestrogen plus progestin regimens;
odds ratios remained similar after these women were
excluded. Conjugated oestrogens were used by only 33
(5.7%) of women who had taken hormone replacement
therapy, and seven of these had also used other types of
hormone replacement therapy. The odds ratio for the
women who were ever users of conjugated oestrogens
only was 0.61 (0.23 to 1.59).
The risk reduction from hormone replacement
therapy diminished with the interval since last use;
after five or more years had elapsed only a 25% overall
reduction in risk remained ( − 7% to 48%) (table 3). The

















Never 956/2073 1.00 (reference) 956/2073 1.00 (reference) 956/2073 1.00 (reference)
Ever: 120/456 0.58 (0.46 to 0.75) 81/229 0.69 (0.52 to 0.93) 56/274 0.46 (0.32 to 0.66)
Current 40/239 0.36 (0.24 to 0.53) 16/62 0.48 (0.26 to 0.87) 24/17 0.29 (0.17 to 0.48)
Former 80/217 0.76 (0.57 to 1.01) 65/167 0.76 (0.56 to 1.04) 32/9 0.71 (0.46 to 1.12)
Per year of use:
Ever 0.94 (0.91 to 0.97) 0.96 (0.92 to 0.99) 0.89 (0.84 to 0.94)
Current 0.91 (0.87 to 0.95) 0.94 (0.88 to 0.99) 0.84 (0.76 to 0.92)
Former 0.97 (0.93 to 1.02) 0.98 (0.92 to 1.04) 0.93 (0.85 to 1.02)
*Adjusted for age (50 to 54, 55 to 59, 60 to 64, 65 to 69, 70 to 74, 75 to 81 years) and the indication of hormone replacement therapy to prevent osteoporosis
(yes/no).
Table 3 Effect of time since last use and duration of hormone replacement therapy on risk of hip fracture
Use of hormone
replacement therapy













Never used 956/2073 1.00 (reference) 956/2073 1.00 (reference) 956/2073 1.00 (reference)
Last use <12 months:
Any use 47/260 0.38 (0.26 to 0.56) 21/70 0.61 (0.35 to 1.04) 28/198 0.28 (0.17 to 0.47)
Total use >5 years 14/97 0.28 (0.16 to 0.51) 8/36 0.35 (0.15 to 0.82) 9/66 0.24 (0.11 to 0.52)
Per year of use 0.92 (0.88 to 0.96) 0.93 (0.88 to 0.98) 0.88 (0.82 to 0.95)
Last use 13-60 months:
Any use 11/45 0.52 (0.26 to 1.04) 9/23 0.82 (0.37 to 1.84) 7/31 0.42 (0.17 to 1.04)
Total use >5 years 3/18 0.27 (0.08 to 0.94) 3/6 0.65 (0.14 to 3.05) 1/12 0.10 (0.01 to 0.87)
Per year of use 0.91 (0.82 to 1.00) 0.97 (0.86 to 1.09) 0.78 (0.63 to 0.97)
Last use >60 months:
Any use 46/125 0.75 (0.52 to 1.07) 38/115 0.65 (0.44 to 0.96) 17/38 1.00 (0.55 to 1.82)
Total use >5 years 15/28 1.07 (0.57 to 2.03) 12/22 1.06 (0.52 to 2.19) 3/8 0.74 (0.19 to 2.93)
Per year of use 0.98 (0.92 to 1.04) 0.98 (0.91 to 1.05) 0.96 (0.83 to 1.12)
*Adjusted for age (50 to 54, 55 to 59, 60 to 64, 65 to 69, 70 to 74, 75 to 81 years) and the indication of hormone replacement therapy to prevent osteoporosis
(yes/no).
Papers
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benefit of long duration of use seemed limited to
women who had taken hormone replacement therapy
within the past five years. Among these women, those
who had a total duration of use longer than five years
had a reduction in risk greater than 70% compared
with never users, but no significant reduction in risk
remained five years after stopping treatment. In
general, within each duration-recency combination,
combined treatment provided lower odds ratios than
oestrogen alone.
Overall, the protective effect of oestrogens on the
risk of hip fracture was dose related. Ever use of a low
dose of medium potency oestrogens did not confer a
protective effect on hip fracture (table 4). With use of
higher doses (equivalent to >2 mg oestradiol or
>0.625 mg conjugated oestrogens) oestrogens without
progestin reduced the risk of hip fracture, but the addi-
tion of progestins was associated with a further reduc-
tion in risk. Similar risk reductions were associated with
oral administration or skin patches but not with injec-
tions. Estimates for injection were imprecise because of
small numbers (data not shown). Similar odds ratios
were obtained in analyses restricted to those who had
used only one route of administration.
Once duration of use was taken into account we
found similar protective effects of treatment whenever
it was initiated in relation to the time of menopause
(table 5). With current use, starting treatment nine or
more years after the menopause gave equally strong
reduction in risk of hip fracture as an earlier start.
Discussion
We found that hormone replacement therapy substan-
tially reduced the risk of hip fracture. The reduction
was greater with higher oestrogen doses and greater
duration of use, but current or recent use of oestrogens
was required for substantial protection. Among women
who had stopped oestrogens more than five years
previously, even long term users had lost most of the
benefit. The addition of progestins permitted use of
lower doses of oestrogens. Oral and transdermal
administration seemed equally effective. Our results
also suggest that treatment can start several years after
menopause without loss of efficiency in reducing
fracture risk.
Comparability
Previous studies have also found a low relative risk of
hip fracture after exposure to exogenous
oestrogens,8–14 although they had limited statistical
power to examine the effects of recency and duration
of use, type of administration, and age at starting
therapy. Other studies support our finding that the
effects of hormone replacement therapy on bone and
hip fracture risk dissipate after stopping treatment. The
Framingham study found a relative risk of 0.34 (95%
confidence interval 0.11 to 1.09 after multivariate
adjustment) among current or recent users of
oestrogen and of 0.70 (0.45 to 1.08) in former users.12
Unfortunately, duration of use was only partially
considered in this analysis. However, two other investi-
gations that did take into account duration of use also
found an apparent loss of benefit.8 14 Studies of bone

















Never used 956/2073 1.0 (reference) 956/2073 1.0 (reference) 956/2073 1.0 (reference)
All:
Low dose† 16/40 0.82 (0.45 to 1.51) 15/29 1.02 (0.53 to 1.96) 1/14 0.13 (0.02 to 1.03)
High dose‡ 80/347 0.55 (0.41 to 0.73) 46/145 0.65 (0.46 to 0.94) 49/245 0.47 (0.33 to 0.69)
Tablet: 97/389 0.54 (0.41 to 0.71) 59/173 0.63 (0.45 to 0.88) 55/262 0.46 (0.32 to 0.67)
Low dose† 14/29 0.93 (0.48 to 1.80) 13/24 1.05 (0.52 to 2.12) 1/7 0.21 (0.02 to 1.77)
High dose‡ 65/300 0.50 (0.36 to 0.68) 31/98 0.61 (0.39 to 0.94) 49/245 0.47 (0.32 to 0.68)
Skin patch: 23/94 0.62 (0.36 to 1.06) 15/46 0.73 (0.38 to 1.40) 12/60 0.49 (0.24 to 1.00)
Low dose† 3/12 0.47 (0.12 to 1.85) 3/6 0.84 (0.18 to 3.82) 0/7 0
High dose‡ 14/76 0.52 (0.28 to 0.98) 7/36 0.49 (0.21 to 1.17) 11/51 0.56 (0.27 to 1.18)
*Adjusted for age (50 to 54, 55 to 59, 60 to 64, 65 to 69, 70 to 74, 75 to 81 years) and the indication of hormone replacement therapy to prevent osteoporosis
(yes/no).
†Equivalent to oestradiol <2 mg/day, conjugated oestrogens <0.625 mg/day, ethinyl oestradiol <10 ìg/day, transdermal oestradiol <50 ìg/day, or any oestradiol given
by injection.
‡Equivalent to oestradiol >2 mg/day, conjugated oestrogens >0.625 mg/day, ethinyl oestradiol >10 ìg/day, transdermal oestradiol >50 ìg /day, or any oestradiol
given by injection.
Table 5 Effect of time after menopause of starting hormone
replacement therapy on risk of hip fracture
Years after menopause at
time of starting treatment
No of cases/
controls Odds ratio* (95% CI)
Never used 956/2073 1.0 (reference)
All users:
<2 61/276 0.53 (0.39 to 0.73)
3-8 19/98 0.48 (0.28 to 0.79)
>9 29/59 0.86 (0.52 to 1.43)
Current users:
<2 16/138 0.29 (0.16 to 0.50)
3-8 7/56 0.30 (0.13 to 0.69)
>9 17/43 0.62 (0.33 to 1.18)
Current users, total use >2 years:
<2 16/107 0.32 (0.18 to 0.58)
3-8 4/33 0.28 (0.10 to 0.82)
>9 3/14 0.26 (0.07 to 1.02)
Last use <5 years:
<2 28/181 0.37 (0.24 to 0.59)
3-8 11/77 0.35 (0.18 to 0.69)
>9 26/52 0.75 (0.43 to 1.32)
Last use<5 years, total use >2 years:
<2 25/130 0.40 (0.24 to 0.65)
3-8 6/40 0.35 (0.14 to 0.84)
>9 5/17 0.36 (0.12 to 1.08)
*Adjusted for age (50 to 54, 55 to 59, 60 to 64, 65 to 69, 70 to 74, 75 to 81
years) and the indication of hormone replacement therapy to prevent
osteoporosis (yes/no).
Papers
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density are also consistent with a waning benefit after
stopping hormone replacement therapy.15 16
Evidence regarding the age at starting treatment is
conflicting. A significant protection from hip fracture
among women who began hormone replacement
therapy within five years after menopause was found in
the study of osteoporotic fractures but not among
women who began later.8 However, in a recent cross
sectional study of bone density, nearly equal bone con-
serving benefit was seen for oestrogen therapy begun
before age 60 years or after if the treatment was
continued.15
We have found no other comparison of the effects
of oestrogen alone and oestrogen plus progestin on
risk of hip fracture. However, consistent with our find-
ings, the study of osteoporotic fractures reported that
compared with never users the relative risk for all frac-
tures was 0.69 (0.56 to 0.86) among current users of
hormone replacement therapy without progestin and
0.51 (0.33 to 0.78) among users of combined
treatment.8 These data and ours clearly suggest that
progestins have a bone sparing effect and are
supported by studies which show that progestins
stimulate osteoblasts and promote bone formation.17 18
Moreover, the addition of progestins to oestrogen
seems to give a better effect on bone density than oes-
trogen alone.19–21
We were able to evaluate dose and type of adminis-
tration on the risk of hip fracture. Skin patches and oral
treatment seemed to confer equally strong risk reduc-
tions, but oestrogen administrated by injection was not
associated with substantial risk reduction. Transdermal
oestradiol has been reported to be effective in prevent-
ing further vertebral bone loss and fractures in women
with established osteoporosis.22
We found that a low dose of oestrogen without
progestins (for example 1 mg of oestradiol or
0.325 mg conjugated oestrogens) was not associated
with a reduction in the risk of hip fracture. This finding
supports the contention that the minimum effective
dose of oestrogen without progestin to prevent
postmenopausal bone loss in most individuals is 2 mg
oestradiol, 0.625 mg conjugated oestrogens daily, or
equivalent.23 24
The mechanism underlying the effect of oestrogen
treatment on bone is not clearly understood but is
thought to involve inhibition of osteoclasts,5 25 which
slows bone turnover and improves the balance
between bone formation and resorption.5 6 Oestrogen
also improves calcium retention through increased
intestinal calcium absorption and renal calcium
reabsorption.26 Oestrogen may also influence other
factors related to fracture risk—for example, extraskel-
etal effects such as improved balance.27 28
Strengths and weaknesses
The strengths of our study are the large size, the popula-
tion based design, and the high response rate. The pre-
cision and validity of our study was augmented by the
thorough ascertainment of exposure, cross checking of
different registers for assessing fractures, and verification
of the diagnosis through hospital records. We did not
include subjects with known senility, alcoholism, and
psychosis, mainly because of the likelihood of inad-
equate recollection. However, the effect of our exclusions
on the overall relative risk is uncertain.
The principal potential limitations of an observa-
tional study such as ours are possible confounding and
measurement error as well as response biases. A
further issue, even in our comparatively large study, is
low statistical power in some subgroups. There was
little indication in our data that known risk factors for
hip fracture confounded the effects of hormone
replacement therapy, but unknown factors could have
distorted our findings. A particular concern is that
women who take hormone replacement therapy may
have a lower risk of fracture for reasons other than the
hormone replacement therapy.
Our case-control study indicates that to prevent hip
fracture hormone replacement therapy may be started
several years after menopause but should be continued
for long periods. Oral or transdermal therapy seem
equally effective, and the addition of progestins
permits lower doses of oestrogens.
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The 1998 European Resuscitation Council guidelines for
adult advanced life support
Advanced Life Support Working Group of the European Resuscitation Council
The publication of guidelines for advanced life support
by the European Resuscitation Council in 1992 was a
landmark in international cooperation and coordina-
tion.1 Previously, individual countries or groups had
produced guidelines,2 but for the first time an
international group of experts produced consensus
views based on the best available information. Since
1992 even wider international collaboration and
support has occurred. In particular, the establishment
of the International Liaison Committee on Resuscita-
tion has facilitated global cooperation and discussion
between representatives from North America, Europe,
Southern Africa, Australia, and most recently Latin
America. The advisory statement produced in 1997 by
the committee forms the basis for these guidelines.3
The 1992 guidelines by the European Resuscita-
tion Council indicated that review would occur on a
regular basis. Change is not advocated for its own sake
and is not warranted without convincing scientific or
educational reasons. Education and its organisation is a
process with a long latency, and it can be confusing and
distracting for trainers and trainees if the message lacks
consistency.
The Advanced Life Support Working Group of the
European Resuscitation Council recognised that the
previous guidelines necessitated a level of rhythm rec-
ognition, interpretation, and subsequent decision mak-
ing that some users found difficult. While automated
external defibrillators ease some of these problems, the
1992 guidelines were not specifically designed for
these devices. These new guidelines are applicable to
manual and automated external defibrillators.
Decision making has been reduced to a minimum
whenever possible. This increases clarity, while still
allowing people with specialist knowledge to apply
their expertise.
Changes in guidelines are only the first step in the
process of care. Their implementation necessitates
considerable effort. Training materials and methods
may require modification, information must be
disseminated, and, perhaps most importantly, evalua-
tion of efficacy is needed. For these purposes, reporting
and publication of out of hospital and in-hospital
cardiac arrest events using the Utstein templates4 5
is strongly advised to provide objective assessment
of outcome.
The limitations of guidelines must be recognised.
As always in the practice of medicine, words and flow
charts must be interpreted with common sense and an
appreciation of their intent. While much is known
about the theory and practice of resuscitation, in many
areas our ignorance is profound. Resuscitation practice
remains as much an art as a science. Furthermore, the
interpretation of guidelines may differ according to the
environment in which they are used. We acknowledge
that individual resuscitation councils may wish to
customise the details while accepting that the guiding
principles are universal. Any such changes must be
approved by the European Resuscitation Council if
they are to be regarded by this organisation as
representing its official guidelines.
Precursors to cardiac arrest
In the so called industrialised world the commonest
cause of adult sudden cardiac death is ischaemic heart
disease.6–9 Prevention of cardiac arrest is to be greatly
preferred to post hoc treatment. The guidelines on the
management of peri-arrest arrhythmias produced by
the European Resuscitation Council in 1994 and
updated in 1996 and 1998 are concerned with treating
arrhythmias that may lead to the development and
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